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and Haiyuan Yu2,3,*
To better understand different molecular mechanisms by which mutations lead to various human diseases, we classified 82,833 disease-
associated mutations according to their inheritance modes (recessive versus dominant) and molecular types (in-frame [missense point
mutations and in-frame indels] versus truncating [nonsense mutations and frameshift indels]) and systematically examined the effects
of different classes of disease mutations in a three-dimensional protein interactome network with the atomic-resolution interface
resolved for each interaction. We found that although recessive mutations affecting the interaction interface of two interacting proteins
tend to cause the same disease, this widely accepted ‘‘guilt-by-association’’ principle does not apply to dominant mutations. Further-
more, recessive truncating mutations in regions encoding the same interface are much more likely to cause the same disease, even
for interfaces close to the N terminus of the protein. Conversely, dominant truncating mutations tend to be enriched in regions encod-
ing areas between interfaces. These results suggest that a significant fraction of truncating mutations can generate functional protein
products. For example, TRIM27, a known cancer-associated protein, interacts with three proteins (MID2, TRIM42, and SIRPA) through
two different interfaces. A dominant truncating mutation (c.1024delT [p.Tyr342Thrfs*30]) associated with ovarian carcinoma is located
between the regions encoding the two interfaces; the altered protein retains its interaction with MID2 and TRIM42 through the first
interface but loses its interaction with SIRPA through the second interface. Our findings will help clarify the molecular mechanisms
of thousands of disease-associated genes and their tens of thousands of mutations, especially for those carrying truncating mutations,
often erroneously considered ‘‘knockout’’ alleles.Introduction
Understanding genotype-to-phenotype relationships has
been a central theme of human genetics.1 In the past few
decades, great progress has been made in identifying and
characterizing disease-associated genes underlying many
Mendelian disorders.2,3 Advances in next-generation-
sequencing technologies and genome-wide association
studies have further facilitated the identification of allelic
variants associated with complex genetic diseases.4,5 How-
ever, it is often unclear how these mutations translate into
complex disease phenotypes. Furthermore, disease-associ-
ated mutations can be classified into different categories
on the basis of their inheritancemodes (dominant or reces-
sive) and molecular types (missense or nonsense). Muta-
tions in different categories might cause disease through
completely different mechanisms at the molecular level
(e.g., loss of function or gain of function).3,6
Given that the cell functions as an intricate molecular
network, disease mutations not only cause aberrations of
single genes but could also perturb the broader network
and lead to the observed phenotype.7–10 Various
network-based approaches have been employed for
exploring genotype-to-phenotype relationships.7–11 Goh
et al. and Feldman et al. found that protein products of
genes associated with similar diseases are more likely to1Department of Molecular Biology and Genetics, Cornell University, Ithaca, N
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modules.8,9 On the basis of this commonly accepted
‘‘guilt-by-association’’ principle,12 many methods have
been developed for the prediction of novel disease-associ-
ated genes with the use of the protein interactome
network.13–15 However, none of these methods have
considered the potential differences in the molecular
mechanisms leading to the corresponding disorders for
mutations of different inheritance modes and molecular
types. Zhong et al. found that disease mutations could
lead to two types of perturbations at the network level:
node removal (loss of all known interactions of a protein)
or edgetic perturbation (loss of specific interactions of a
protein).11 They also found that a higher fraction of muta-
tions associated with autosomal-dominant diseases are in-
frame, tend to affect structural proteins, and are likely to
affect exposed residues.11
The functional consequences of different classes of dis-
ease mutations can be better characterized by the consider-
ation of the three-dimensional (3D) structures of proteins.
Recent studies have shown that incorporating structural
information with the protein-protein interaction network
provides mechanistic understanding of disease-associated
genes and mutations at the molecular level.6,16 In a previ-
ous study, we established a high-quality 3D protein inter-
actome network with structurally resolved interfaces forY 14853, USA; 2Weill Institute for Cell and Molecular Biology, Cornell Uni-
tational Biology, Cornell University, Ithaca, NY 14853, USA; 4Department of
Y 10021, USA
y of Human Genetics. All rights reserved.
each interaction.16 We analyzed in-frame disease muta-
tions affecting this 3D interactome network and found
that disease specificity of in-frame mutations can be ex-
plained by the locations they affect within the correspond-
ing interaction interfaces.16
However, to date, no systematic analysis has been done
to examine the widely-used guilt-by-association principle
on disease mutations with different inheritance modes
and molecular types, which is the focus of this study.
We compiled a comprehensive set of disease-associated
mutations from the Human Gene Mutation Database
(HGMD)17,18 and the Catalogue of Somatic Mutations in
Cancer (COSMIC).19,20 We then annotated the inheritance
modes of disease mutations on the basis of manually
curated inheritance information. We further expanded
the 3D protein interactome network with 668 additional
high-quality binary interactions.16 Structural details of
protein interactions provide a tool for examining the
effects of different types of disease mutations at atomic res-
olution. Here, we applied this approach to systematically
analyze disease mutations of different inheritance modes
and molecular types, which can be divided into four cate-
gories (i.e., dominant in-frame, dominant truncating,
recessive in-frame, and recessive truncating). First, we
examined how the effects of disease mutations in different
categories were distributed in proteins with respect to
interaction interfaces. We then investigated to what extent
the guilt-by-association principle can be applied to pairs of
mutations that are in different categories and that affect
different locations in the corresponding proteins. We
found that the guilt-by-association principle does not
apply to dominant disease mutations (both in-frame and
truncating). Furthermore, we found that 61% of recessive
truncating mutation pairs in regions encoding the same
interaction interface cause the same disease; this percent-
age is significantly higher than that for mutations in re-
gions encoding different interfaces (12%). This analysis
was not performed in our previous study,16 and our results
indicate that a significant fraction of truncating mutations
can generate protein products that retain at least some of
the wild-type functions, contrary to the common belief
that truncating mutations are often complete loss-of-func-
tion mutations.21–24Material and Methods
Compiling a High-Quality List of Disease-Associated
Genes and Mutations
Somatic mutations and their associated cancers were obtained
fromCOSMIC19,20 (version 56). To remove putative passenger mu-
tations, we only included mutations in genes in the Cancer Gene
Census.25–28 Germline mutations and their associated diseases
were obtained from HGMD17,18 (professional version 2010.12).
Only ‘‘disease-causing mutations’’ and ‘‘disease-associated poly-
morphisms of functional significance’’ were selected for further
analyses. Each mutation and its flanking sequence was translated
into an amino acid sequence andmapped onto the correspondingTheprotein sequence. Protein sequences used were obtained from
SwissProt29 (release 57.6).
The nomenclatures of diseases are not standardized between the
two databases. We compiled a comprehensive disease-gene associ-
ation map based on the Online Mendelian Inheritance in Man
(OMIM)2 and HGMD databases and gave unique disease IDs to
each phenotypically distinct disorder. To standardize the nomen-
clature, we mapped all disease names to our disease IDs through
bioinformatic processing and manual curation.
Constructing the 3D Protein Interactome Network
The human 3D protein interactome network was constructed as
previously described in Wang et al.16 Since the publication, the
3D protein interactome network has been continuously up-
dated.30 New binary protein interactions have been incorpo-
rated.31 Furthermore, in Wang et al.,16 binary protein interactions
that are supported by only one cocrystal structure and have no
other supporting evidence in the literature were excluded from
the 3D protein interactome network for quality assurance. Here,
we modified our filtering criteria to include all binary protein in-
teractions supported by cocrystal structures in 3did32 or iPfam,33
given that cocrystal structures are usually considered gold-
standard evidence that these interactions exist. Our homology-
modeling approach assigns each interface domain with specific
interactions of that protein, and one interaction could have mul-
tiple interface domains. If two proteins interact through multiple
domains, all domains involved in the interaction are considered to
be the interaction interface. If each of the two interacting proteins
has other domains that interact with other proteins, these
different domains are classified as different interfaces for different
interactions. To evaluate the performance of our homology-
modeling approach, we carried out 3-fold cross-validation by
using the 1,456 human interaction pairs with known cocrystal
structures. We found that over 94% of these interactions were
correctly predicted with corresponding interaction interfaces,
indicating the high accuracy of our approach.16 Currently, our
homology-modeling approach cannot account for protein-pep-
tide interactions, given that it is extremely difficult to predict pro-
tein-peptide interactions with high accuracy.34
Annotating the Inheritance Modes
Inheritance information of disease-associated genes was obtained
from two sources: Zhong et al.11 and the Cancer Gene Census.35
Each unique gene-disease pair was assigned either autosomal-
dominant or autosomal-recessive inheritance. Gene-disease pairs
with other inheritance patterns, e.g., sex-linked inheritance,
were discarded. Gene-disease pairs with conflicting annotations
in the two data sets were removed. In total, we collected inheri-
tance patterns for 1,794 unique gene-disease pairs. Next, we
separated mutations into either autosomal-dominant or auto-
somal-recessive inheritance on the basis of the genes in which
they reside and the disease with which they are associated. A total
of 38,497 disease-associated mutations with either autosomal-
dominant or autosomal-recessive inheritance were obtained.
Statistical Analysis: Distribution of Mutations with
Respect to Regions Encoding Interaction Interfaces
Proteins affected by at least one mutation and with at least one
interaction domain were chosen for the mutation enrichment
calculation. Each protein sequence was divided into three regions:
‘‘in interaction interface,’’ ‘‘in other domain,’’ and ‘‘outsideAmerican Journal of Human Genetics 93, 78–89, July 11, 2013 79
domains.’’ The total number of amino acids and the total
number of mutations affecting each region were counted. If
mutations are randomly distributed, the fraction of mutations
affecting each region should be proportional to the relative
length of each region. We calculated the expected fraction of
mutations affecting each region (p2) by dividing the sum of
the sequence length of each region in all proteins by the sum
of the total sequence length of all proteins. We calculated the
observed fraction of mutations affecting each region (p1) by add-
ing mutations affecting each region of all proteins and dividing
the sum by the total number of mutations. The odds ratios
(ORs) were calculated on the basis of these expected and observed
fractions:
OR ¼ p1=ð1 p1Þ
p2=ð1 p2Þ:
Z scores and the 95% confidence intervals for the ORs36 were
calculated as follows:SElog odds ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nmut;region
þ 1
nmut;total  nmut;region þ
1
nres;region
þ 1
nres;total  nres;region
s95% CIlog odds ¼ ln OR5

N0:9753 SElog odds

Z ¼ lnðORÞ
SElog odds
;
where N0.975 is the 97.5
th percentile value of the standard normal
distribution, nmut is the number of mutations, and nres is the total
number of residues.Statistical Analysis: Locus Heterogeneity Calculations
Mutation Pairs Affecting Interaction Partners
Genes with at least onemutation affecting an interaction interface
and encoding proteins with at least one interaction interface were
selected for this calculation. Of all mutations in these genes, only
mutations affecting interaction interfaces were used and muta-
tions not affecting interaction interfaces were discarded. From
this list of genes, all possible pairs of genes in which at least one
of the two genes encodes a protein withmore than one interaction
interface were selected.
For each gene pair, all possible mutations pairs with one
mutation affecting an interaction interface encoded by gene A
and another mutation affecting an interaction interface encoded
by gene B were considered. We divided all mutation pairs into
three categories: (1) if genes A and B encode interacting proteins
in the 3D protein network and both mutations affect the
interaction interface responsible for the interaction between the
proteins encoded by genes A and B, we considered the mutation
pair to ‘‘affect the same interface;’’ (2) if at least one of the two
mutations does not affect the interaction interface between
the proteins encoded by genes A and B, we considered the
mutation pair to ‘‘affect other interaction interfaces;’’ and (3) if
genes A and B do not encode interacting proteins, we considered
the mutation pair to be ‘‘noninteracting.’’ We then calculated the
percentage of mutation pairs causing the same disease for
each category. The statistical significance of the comparisons80 The American Journal of Human Genetics 93, 78–89, July 11, 2013between categories was evaluated by the cumulative binomial
distribution
pðcRcoÞ ¼
XN
c¼co

N!
N!ðN  cÞ!

pcð1 pÞNc;
where N is the total number of mutation pairs, co is the number of
observed pairs causing the same disease, and p is the fraction of
pairs causing the same disease in the control sample. In all calcu-
lations, the binomial test was performed twice, and the test and
control groups were swapped in the second test. The least signifi-
cant p value was used.
Effect of Mutation Location on Locus Heterogeneity
All genes with at least one mutation were selected. All possible
pairs of genes encoding proteins that interact in the 3D protein
network were used. For each gene pair, gene A was divided into
three equal parts and mutations on each third were paired with
all gene Bmutations affecting the corresponding interaction inter-face. All mutation pairs were classified into two categories: (1) if
the mutation in gene A also affects the corresponding interaction
interface with the protein encoded by gene B, the mutation pair
was considered to ‘‘affect the interaction interface,’’ or (2) the
mutation pair was classified as ‘‘other.’’ For each gene pair, both
genes were used once as gene A and once as gene B. The statistical
significance of the difference between the two categories for each
third was evaluated by the cumulative binomial distribution as
described above.Statistical Analysis: Enrichment of Truncating
Mutations in Sequences Encoding the Interdomain
Regions
In this study, an interdomain region was defined as a region
between two different interaction interfaces on a protein. Two
interaction interfaces on a protein were considered different if at
least one protein interacts with one interface, but not the other,
in the 3D protein interaction network. Genes with at least one
truncatingmutation and encoding proteins with at least one inter-
domain region were selected for further analyses. The enrichment
of dominant and recessive truncating mutations in sequences
encoding the interdomain regions was measured by an OR as
detailed above. Sample sizes in all the calculations are listed in
Table S1, available online.Identification of Loss-of-Function Dominant
Mutations
Huang et al.37 have made a genome-wide prediction of the pro-
bability of genes to exhibit haploinsufficiency. On the basis of their
predicted probability scores of being haploinsufficient (HI), p(HI),
we considered the top 10% of genes with the highest p(HI) as HI
genes. To validate the predicted HI gene set, we checked whether
the predicted HI genes tend to be dominantly inherited. Among
583 dominantly inherited genes, 161 were predicted to be HI
genes, whereas only 32 out of 515 recessively inherited genes were
predicted to be HI. The enrichment of dominantly inherited genes
in the HI gene set verified the prediction accuracy. We classified
all dominant mutations on HI genes as ‘‘HI mutations’’ and all
dominant mutations not on HI genes as ‘‘non-HI mutations.’’
Selection of Proof-of-Principle Example for
Experimental Validation
To experimentally validate our hypothesis that protein products of
alleles with truncating mutations in sequences encoding the
interdomain regions can retain some of their original functions
or interactions, we searched for dominant truncating mutations
satisfying the following criteria: (1) Themutation has to be located
between regions encoding two different interaction interfaces. (2)
Dominant truncating mutations have to be enriched in the
sequence encoding the interdomain region. (3) To test the conser-
vation and loss of specific interactions of the truncated protein
with yeast two-hybrid (Y2H) assays, the interactions between the
wild-type protein and its interactors at different interaction inter-
faces must be detectable by our Y2H pipeline. TRIM27 (MIM
602165) c.1024delT (p.Tyr342Thrfs*30) was chosen for experi-
mental validation because it satisfies all the above requirements
and we have existing clones of TRIM27, SIRPA (MIM 602461),
MID2 (MIM 300204), and TRIM42.
Determination of Interaction Interfaces with the Use
of the 3D Protein Interaction Network and Structural
Interface Matching
Using a combination of the 3D protein interaction network and
structural interface matching, we determined domains mediating
interactions between TRIM27 and SIRPA, TRIM27 and MID2, and
TRIM27 and TRIM42. Structural interface matching comprised
two steps—rigid body docking and flexible docking.38 For putative
interacting domains, crystal structures were obtained from the
Protein Data Bank (PDB) (see Web Resources).39 Only high-resolu-
tion (<2.5A˚) X-ray-diffraction structures were used. Rigid body
docking was performed with Patchdock40,41 with default parame-
ters. This was followed by backbone refinement of the two pro-
teins with the use of normal-mode analysis.42 Finally, both the
side chain and the backbone conformations were refined with
the computationally efficient FiberDock algorithm with default
parameters.43,44 We found that a SPRY domain on TRIM27 and a
C1-set domain on SIRPA mediate the interaction between
TRIM27 and SIRPA. We found an energetically feasible solution
by docking the SPRY domain (PDB ID 2YYO, crystallized by
the RIKEN Structural Genomics/Proteomics Initiative) and the
C1-set domain (PDB ID 2WNG).45 Both the TRIM27-MID2 and
TRIM27-TRIM42 interactions are mediated by zf-B box domains
on the corresponding proteins. The energetic feasibility of dimer-
ization of the zf-B box domain is demonstrated by a cocrystal
structure (PDB ID 2YVR, crystallized by the RIKEN Structural
Genomics/Proteomics Initiative).
Construction of Plasmids and Disease Mutant Clones
Wild-type TRIM27, MID2, TRIM42, and SIRPA entry clones
are from the hORFeome 3.1 collection.46 To generate disease
mutant clones, we performed PCR mutagenesis as previously
described.11,16,47 In brief, wild-type TRIM27 in an activation
domain (AD) vector was used as the template in PCR reactions
for the generation of N- and C-terminal fragments, each con-
taining the region affected by the desired mutation in their
overlapping region. BP recombination reactions were performedTheaccording to the manufacturer’s manual (Gateway BP Clonase II
Enzyme Mix, catalog number 11789-020) for moving mutant
clones into the entry vector.Y2H
Y2H was performed as previously described.48 In brief, wild-type
and mutant TRIM27 were transferred into AD vectors. Wild-type
MID2, TRIM42, and SIRPA were transferred into DNA-binding
(DB) vectors. AD and DB constructs were transformed into Y2H
strains MATa Y8800 and MATa Y8930, respectively. Transformed
yeast were spotted onto YPD plates and incubated at 30C for
~20 hr before replica plating onto synthetic complete (SC) plates
lacking Leu and Trp. Yeast cells were allowed to grow at 30C for
24 hr before replica plating onto each of the four selection plates
(SC-Leu-Trp-His, SC-Leu-HisþCYH, SC-Leu-Trp-Ade, and SC-Leu-
AdeþCYH). At 72 hr after replicating, plates were evaluated for
protein interactions.Results
Mapping the Effects of Disease Mutations onto the 3D
Protein Interactome Network
Here, we have compiled a comprehensive list of human
disease mutations, including 68,789 germline mutations
in 2,781 genes associated with 2,244 phenotypically
distinct Mendelian diseases from HGMD17,18 and 14,044
somatic cancer mutations in 366 genes associated with
112 cancers from COSMIC.19,20 Because COSMIC includes
results from whole-genome-sequencing experiments, it is
likely that some mutations identified are passenger muta-
tions that do not cause the cancer phenotype. To remove
putative passenger mutations from the COSMIC data set,
we included only mutations in genes in the Cancer Gene
Census,35 a literature-curated list of known cancer-associ-
ated genes.
Disease mutations can be dominant or recessive at the
cellular level. For dominant mutations, a single mutated
allele can lead to pathogenesis, whereas for recessive muta-
tions, both alleles need to be mutated for disease to occur.
To examine the potential differences between dominant
and recessive mutations, we compiled a list of genes with
manually curated inheritance and disease information
from published data sets.11,35 Disease mutations were
then classified as autosomal dominant or autosomal reces-
sive according to the inheritance mode of the respective
gene and the disease they are associated with. In total,
we annotated the inheritance modes of 38,497 disease-
associated mutations.
Using our recently developed homology-modeling
approach16 and incorporating newly published binary
protein-protein interactions, we generated a high-quality
3D atomic-resolution protein interactome network com-
prising 4,890 structurally resolved interactions involving
3,174 proteins (Figure 1A). A total of 11,290 dominant
mutations and 8,702 recessive mutations were mapped
onto their corresponding proteins in the 3D protein inter-
actome network.American Journal of Human Genetics 93, 78–89, July 11, 2013 81
A B C
D E
Dominant Recessive
In-frame Truncating
In-frame
Truncating
Dominant
Recessive
0 diseases
1-2 diseases
3-9 diseases
10+ diseases
Dominant
Recessive
Both
Figure 1. Disease-Associated Genes and
Mutations Affecting the 3D Protein Inter-
actome Network
(A) Network representation of the structur-
ally resolved protein interactome.
(B) Proportions of in-frame and truncating
mutations among all dominantmutations.
(C) Proportions of in-frame and truncating
mutations among all recessive mutations.
(D) Proportions of dominant and recessive
mutations among all in-frame mutations.
(E) Proportions of dominant and recessive
mutations among all truncating muta-
tions.Different Molecular Mechanisms between Dominant
and Recessive Mutations
All disease mutations can be further divided into two
broad classes according to their molecular types and
effects on the translated protein products: missense point
mutations and in-frame insertions or deletions are classi-
fied as in-frame mutations; nonsense mutations and
frameshift insertions or deletions are classified as trun-
cating mutations.11,16 In-frame alleles are likely to produce
full-length protein products with local defects, whereas
truncating alleles, which are also called ‘‘complete loss-
of-function (LoF)’’ alleles,21 are often assumed not to pro-
duce any functional protein products, especially in many
current whole-exome- and whole-genome-sequencing
studies.22–24,49
Among the dominant mutations, 67% are in-frame,
whereas 60% of the recessive mutations are in-frame (Fig-
ures 1B and 1C). Conversely, 52% of in-frame mutations
are dominant, whereas only 44% of truncating mutations
are dominant (Figures 1D and 1E). The results agree with
our current knowledge of the mechanisms of the action
of dominant mutations. Other than the case of haploinsuf-
ficiency, dominance is most often a result of gain-of-func-
tion mutations or dominant-negative mutations, where
the altered protein product is activated for a specific func-
tion or interferes with the normal function(s) of the wild-
type protein.11,50 Therefore, most dominant mutations
should translate into specific localized changes in the pro-
tein, which can be more easily achieved with in-frame
mutations than with truncating mutations.
Most proteins carry out their functions through interac-
tions with other proteins. Our recent study has demon-
strated that the disruption of specific interactions of a
protein is an important mechanism for pathogenesis
of many human disease-associated genes and their82 The American Journal of Human Genetics 93, 78–89, July 11, 2013mutations.16 To further investigate
the differences between dominant
and recessive disease mutations, we
mapped the mutations onto their cor-
responding proteins in the 3D protein
interactome and examined the loca-
tions they affect with respect to inter-
action interfaces and other functionalprotein domains. We found that for recessive mutations,
both in-frame and truncating mutations are significantly
enriched in regions encoding interaction interfaces
(OR ¼ 3.3, p < 1020 by Z-test and OR ¼ 1.9, p < 1020
by Z-test; respectively, Figure 2B). Because recessive muta-
tions are more likely to be loss-of-function mutations,6,51
our results demonstrate that the disruption of protein
interaction interfaces is a common mechanism leading to
the loss of specific functions. Dominant in-frame muta-
tions are also enriched in regions encoding interaction in-
terfaces (OR ¼ 1.5, p < 1020 by Z-test, Figure 2A). Because
a significant fraction of dominant mutations are gain-of-
function mutations,6,51 the results suggest that changes
in protein interaction interfaces not only lead to the loss
of specific interactions but also have the potential to
generate new ones. Remarkably, the dominant truncating
mutations are enriched in regions encoding sequences
outside of functional domains (OR ¼ 3.6, p < 1020 by
Z-test, Figure 2A) and are depleted in regions encoding pro-
tein interaction interfaces. This shows that the molecular
mechanisms of dominant truncating mutations tend to
be distinct from their recessive counterparts. To further
assess the differences between dominant and recessive
mutations, we next investigated the disease specificity of
mutations in different categories.
The Guilt-by-Association Principle Does Not Apply to
Dominant Mutations
Many genetic diseases show locus heterogeneity, whereby
a disease is associated with mutations on more than one
gene. Understanding how different genes converge func-
tionally to associate with the same disorder has important
implications in the search for novel disease-associated
genes and drug targets. Previous studies have shown that
interacting protein pairs are more functionally similar
AB
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In-frame mutations Truncating mutations
 Location with respect to interfaces  Location with respect to interfaces
Truncating mutations
 Location with respect to interfaces Location with respect to interfaces
Recessive mutations
In-frame mutations
Figure 2. Distribution of Recessive and
Dominant DiseaseMutations with Respect
to Regions Encoding Interaction Inter-
faces
(A) ORs of the distributions of dominant
in-frame (left) and truncating (right) muta-
tions in sequences encoding different pro-
tein regions.
(B) ORs of the distribution of recessive in-
frame (left) and truncating (right) muta-
tions in sequences encoding different pro-
tein regions. **p < 1020, *p < 1010. The
p values were calculated with Z-tests for
the log OR. Error bars represent 95% confi-
dence intervals of ORs.and tend to be associated with the same diseases.12,52 More
specifically, it has recently been shown that two in-frame
mutations affecting the corresponding interaction inter-
faces of two interacting proteins tend to cause the same
disease.16 This provides a higher-resolution explanation
for the guilt-by-association principle: mutations affecting
the interaction interface of two interacting proteins
disrupt the same interaction in the cellular network and
therefore abolish the same function and cause the same
disorder.
To investigate whether the guilt-by-association principle
holds for both dominant and recessive mutations, we
examined the likelihood that in-frame mutation pairs
affecting two different proteins cause the same disease.
Among recessive in-frame mutations, 88% of mutation
pairs affecting the corresponding interfaces of two interact-
ing proteins cause the same disease; this percentage is
significantly higher than that of mutation pairs affecting
interaction interfaces that are not responsible for the inter-
action between the two proteins (21%, p< 1020 by cumu-
lative binomial test; Figure 3A, left). In contrast, among
dominant in-frame mutations, only 10.1% of mutation
pairs affecting the corresponding interfaces of interacting
proteins cause the same disorder. Furthermore, the proba-
bility that two dominant in-frame mutations affecting in-
teracting proteins cause the same disease does not depend
on whether the two mutations affect the corresponding
interaction interface responsible for the interaction
between the two proteins or on other interaction interfaces
(10.1% or 10.6%, respectively; Figure 3B, right). To further
investigate the possible mechanisms of truncating muta-
tions, we repeated the above calculation with truncating
mutations. Interestingly, the observed difference between
dominant and recessive in-frame mutations can also beThe American Journal of Huseen among truncating mutations
(Figure 3B). The likelihood that
recessive truncating mutation pairs
affecting interacting proteins cause
the same disease depends on their
location relative to the region encod-
ing the interaction interface (Fig-
ure 3B, left). In contrast, dominanttruncating mutation pairs affecting interacting proteins
are less likely to cause the same disease, regardless of their
location (Figure 3B, right). Just like to in-frame mutations,
the guilt-by-association principle applies well to recessive
truncating mutations, but not to dominant ones.
An interesting example of the guilt-by-association prin-
ciple can be observed in Glanzmann thrombasthenia
(MIM 273800), which is associated with recessive muta-
tions affecting the corresponding interaction interfaces
of both ITGA2B and ITGB3. On the other hand, dominant
mutations affecting the interaction interface of two pro-
teins are often associated with different diseases. For
example, dominant mutations affecting the calcium-
binding epidermal growth factor domains of FBN1 are
associated with Marfan syndrome (MIM 154700), whereas
dominant mutations affecting the corresponding interac-
tion interface of FBN2 are associated with contractural
arachnodactyly (MIM 121050). Although Marfan syn-
drome and contractural arachnodactyly are related dis-
eases, they have distinct clinical phenotypes.53
Our guilt-by-association analysis demonstrates that
although recessive mutations that affect two different pro-
teins and disrupt the same interaction tend to cause the
same disorder, the same principle cannot be extended to
dominant mutations. A likely explanation for these results
is that loss-of-function mutations affecting two interacting
proteins often cause the same disease by disrupting the
same edge in the interaction network, but gain-of-function
mutations affecting interacting proteins are less likely to
cause the same disease because mutations in two different
genes rarely gain the same function. Whereas recessive
mutations aremore likely to be loss-of-functionmutations,
dominant mutations can be gain-of-function, dominant-
negative, or loss-of-function mutations (in the case ofman Genetics 93, 78–89, July 11, 2013 83
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Figure 3. Analysis of Locus Heterogeneity among Dominant and Recessive Disease Mutations
(A) Percentage of recessive (left) or dominant (right) in-frame mutation pairs that affect two different proteins and cause the same
disease.
(B) Percentage of recessive (left) or dominant (right) truncating mutation pairs that affect two different proteins and cause the same
disease. Error bars represent5 SE. The p values were calculated with cumulative binomial tests.haploinsufficiency). To differentiate the molecular mecha-
nisms of different classes of dominant mutations, we
divided all dominant mutations into two categories—
those likely to cause disease through haploinsufficiency
(haploinsufficient [HI] mutations) and those not likely to
cause disease through haploinsufficiency (non-HI muta-
tions)—on the basis of a genome-wide prediction of HI
genes.37 We found that compared to two non-HI in-frame
mutations affecting the corresponding interfaces of inter-
acting proteins, two HI in-frame mutations affecting the
corresponding interaction interfaces between interacting
proteins are significantly more likely to cause the same dis-
ease (p < 1020 by cumulative binomial test; Figure 4A).
Our results support the idea that because a large fraction
of dominant mutations are gain-of-function variants, the
guilt-by-association principle does not apply to these
mutations. A similar calculation could not be performed
on truncating mutations because of the small sample
size. However, we found a clear distinction in the distribu-
tion patterns of HI and non-HI truncating mutations on84 The American Journal of Human Genetics 93, 78–89, July 11, 2013their corresponding proteins. Similar to recessive trun-
cating mutations, HI truncating mutations are enriched
in regions encoding protein interaction interfaces. In
contrast, non-HI truncating mutations are highly enriched
in regions encoding sequences outside of functional
domains (Figure 4B). This suggests that truncating muta-
tions can also cause loss or gain of specific functions
through distinct molecular mechanisms. Furthermore,
themode of action of truncating mutations can be inferred
from their locations with respect to the regions encoding
the interaction interfaces.
Truncating Alleles Can Give Rise to Functional
Products
Currently, truncating mutations are most often regarded
as ‘‘knockout’’ mutations leading to absent or nonfunc-
tional protein fragments.11,16 This is because mRNAs
harboring premature stop codons are known to be
selectively degraded by nonsense-mediated mRNA decay
(NMD),54,55 and furthermore, even if the mRNA is
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Figure 4. Analysis of Different Molecular Mechanisms of Dominant Mutations
(A) Percentage of HI and non-HI in-frame mutation pairs that affect two different proteins and cause the same disease.
(B) ORs of the distribution of HI and non-HI truncating mutations in sequences encoding different regions of proteins. Error bars
represent5 SE. The p values were calculated with cumulative binomial tests.translated, the resultant protein fragment is unlikely to
fold into a stable product. If most of the truncating
mutations lead to the loss of protein product, truncating
mutations should be randomly distributed across protein-
coding regions. However, in Figure 2 we observe that reces-
sive truncating mutations are specifically enriched and
dominant truncating mutations are specifically depleted
in regions encoding protein interaction interfaces. Figure 3
further shows that truncating mutations with different
inheritance modes have different patterns of disease asso-
ciation and that pairs of recessive truncating mutations
in regions encoding the same interaction interface are
much more likely to cause the same disease than those in
regions encoding different interfaces. These results suggest
that, contrary to common belief, a significant portion of
truncating mutations are translated into functional pro-
tein products.
Truncating mutations in regions encoding sequences
near the N terminus delete larger fractions of the wild-
type protein. Therefore, it is generally believed that alleles
carrying truncating mutations in regions encoding se-
quences near the N terminus are even less likely to produce
functional products. In this study, we investigated how
location with respect to the N terminus affects the func-
tional consequences of truncating mutations. We first clas-
sified all truncating mutations into three categories: (1)
mutations that are in regions encoding sequences near
the N terminus and that truncate more than two-thirds
of the wild-type protein, (2) mutations that are in regions
encoding sequences near the C terminus and that truncate
less than one-third of the wild-type protein, and (3) muta-
tions that are in regions encoding the middle of the pro-
tein and that truncate between one-third and two-thirds
of the wild-type protein. Then, for each pair of interacting
proteins, we calculated in each category the percentage of
truncating mutations that cause the same disease as muta-Thetions in regions encoding the corresponding interaction
interfaces of the interaction partner (Figure 5 and Fig-
ure S5). If most truncating mutations in regions encoding
sequences near the N terminus cause complete loss of func-
tion, all pairs of these mutations should have the same
likelihood of causing the same disease, irrespective of
whether they are in regions encoding the same interacting
interface or not. However, we found that regardless of their
location relative to the region encoding the N terminus,
recessive truncating mutations in regions encoding the
corresponding interaction interfaces of two proteins are
always more likely to cause the same disease than are those
that are not in regions encoding the corresponding inter-
action interfaces (Figure 5). Furthermore, we also found
that irrespective of their location relative to the region
encoding the N terminus, dominant truncating mutations
are always enriched in regions encoding sequences outside
of interaction interfaces and that recessive truncating
mutations are always enriched in regions encoding interac-
tion interfaces (Figure S6). These results show that trun-
cating mutations’ location relative to the region encoding
the N terminus does not significantly alter the proportion
of truncated proteins that retain specific functions. These
results, together with our observations in Figures 2–4,
confirm that a significant fraction of alleles carrying
truncating mutations, even those in regions encoding
sequences near the N terminus, can be translated into pro-
teins with specific functions.
To further characterize the molecular mechanisms un-
derlying dominant and recessive truncating mutations,
we calculated the enrichment of disease-associated trun-
cating mutations that occur in regions encoding
sequences between two different interaction interfaces.
We found that dominant truncating mutations are en-
riched in regions encoding sequences located between
interaction interfaces (OR ¼ 1.7, p < 1020 by Z-test) andAmerican Journal of Human Genetics 93, 78–89, July 11, 2013 85
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Figure 5. Disease Specificity of Truncating Mutations in Sequences Encoding Different Regions of the Protein
Percentage of truncating (A) or in-frame (B) mutations that are in regions encoding different parts of the protein and that cause the same
disease as mutations affecting its interaction partner. Error bars represent5 SE. The p values were calculated with cumulative binomial
tests.that recessive truncating mutations are depleted in regions
encoding sequences located between interaction interfaces
(OR ¼ 0.74, p < 105 by Z-test; Figure 6A and Figure S7).
This result confirms that dominant truncating mutations
tend to preserve specific interactions while losing others.
To experimentally validate our conclusions, we tested
the interactions of the protein product of tripartite-motif-
containing 27 (TRIM27), a known cancer-associated gene
that acts dominantly in oncogenesis.35,56 A frameshift
deletion (p.Tyr342Thrfs*30 [c.1024delT]) occurring just
before the SPRY domain of TRIM27 was found to be asso-
ciated with ovarian carcinoma (MIM 167000).20,57 Using
a combination of the 3D protein interaction network and
structural interface matching, we found that TRIM27
interacts with three other proteins, MID2, TRIM42, and
SIRPA, of which only SIRPA interacts exclusively with the
SPRY domain in TRIM27 (Figure 6B). None of the three
interaction partners of TRIM27 were previously known to
be involved in ovarian cancer. Here, we tested the
interactions of wild-type TRIM27 and truncated TRIM27
by using Y2H. Because the truncating mutation occurs
after the interaction interfaces with MID2 and TRIM42
but before the interaction interface with SIRPA, we
hypothesized that the truncated TRIM27 would lose its
interaction with SIRPA while retaining the other two
interactions. The Y2H results confirm that the truncating
mutation only disrupts the TRIM27-SIRPA interaction
and leaves the other two interactions unaffected (Fig-
ure 6C). This supports our hypothesis that truncating
mutations can retain specific interactions or functions.
This result also suggests that abolition of the interaction
between TRIM27 and SIRPAmight contribute to the cancer
phenotype and that SIRPA might be associated with
ovarian carcinoma.Discussion
One challenge in deciphering the molecular basis of
genetic diseases is that disease phenotypes are often associ-
ated with multiple mutations that are in different genes86 The American Journal of Human Genetics 93, 78–89, July 11, 2013and that have variable associated risks. Studies have found
that genes associated with the same disease tend to cluster
in functional modules within biological networks.8,9 This
guilt-by-association principle has been widely applied for
the identification of novel disease-associated genes.58
However, the accuracy of these predictions is still relatively
low.59 Here, we systematically dissected the guilt-by-associ-
ation principle on the basis of the molecular types and
inheritance modes of over 20,000 mutations. Although
recessive disease mutations affecting the corresponding
interaction interfaces of interacting proteins tend to cause
the same disease, the same does not apply to dominant dis-
ease mutations. Although current tools that predict dis-
ease-associated genes have integrated the protein-protein
interactome network with disease phenotypic information
to improve the accuracies of predictions,13–15 none of the
current prediction models incorporate the difference in in-
heritance modes of disease-associated genes. By pointing
out that the guilt-by-association principle only applies
to recessive mutations, our findings could significantly
improve the accuracy of current prediction methods for
disease-associated genes.
Furthermore, truncating mutations, also called LoF
mutations, are often regarded as knockout mutations in
large-scale mutational screens and genome-sequencing
projects.21–24,49 However, there are instances reported
where mRNAs harboring truncating mutations escape
NMD and are translated into proteins with dominant-
negative activities.60,61 One particularly interesting case
study involving SOX10 (MIM 602229) demonstrated that
truncating mutations in different regions of SOX10 confer
distinct neurological phenotypes. Among all SOX10 alleles
harboring nonsense or frameshift mutations, transcripts
with mutations in exons 3 and 4 are targeted by NMD,
causing a neurological phenotype called Waardenburg-
Shah syndrome (MIM 277580). On the other hand, tran-
scripts with mutations in exon 5 escape NMD and lead
to a more severe phenotype as a result of the dominant-
negative effects of the translated protein.61 Furthermore,
a recent publication revealed that, contrary to common
belief, only a small percentage (16.3%) of LoF alleles
AB
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Figure 6. Enrichment of Truncating Mutations in Regions En-
coding Sequences between Two Interaction Interfaces
(A) ORs of dominant and recessive truncating mutations affecting
regions between interaction interfaces. **p< 1020, *p< 0.05. The
p values were calculated with Z-tests for the log OR. Error bars
represent 95% confidence intervals of ORs.
(B) Illustration of TRIM27 and its interaction interfaces withMID2,
TRIM42, and SIRPA. The colored star indicates the location of the
experimentally tested mutation (c.1024delT [p.Tyr342Thrfs*30]).
(C) Y2H-tested effects of truncating mutation c.1024delT
(p.Tyr342Thrfs*30) on the interactions of TRIM27.show significant evidence of NMD.21 Our results further
suggest that it is overly simplistic to consider all truncating
mutations as null mutations, given that a significant frac-
tion of them do generate functional protein products.
Interestingly, our results show that truncating mutations
that lead to functional products are not limited to the
extreme C-terminal region of proteins; many proteins
can lose more than two-thirds of their length and still
retain specific functions.
All results that we discussed above are robust to the
removal of protein hubs and domain hubs (Figures S1–
S4), confirming that these results are not biased by overrep-
resented proteins or domain families. Moreover, although
filtering COSMIC mutations within Cancer Gene Census
genes enriches for cancer-causing mutations (Figure S10)Theand this filtering scheme is often used for selecting a
high-confidence set of cancer mutations,25–28 some of
the filtered mutations might still be passenger mutations.
Therefore, we repeated our calculations by using only the
HGMD mutations, and all results remained the same (Fig-
ures S8 and S9). These results indicate that although cancer
is a complex disease, cancer-causingmutations are likely to
disrupt normal protein functions through similar biophys-
ical and/or biochemical mechanisms at the molecular level
as are Mendelian mutations.
In recent years, large numbers of mutations have
been discovered from whole-genome- and whole-exome-
sequencing studies. Popular tools such as PolyPhen-2,62
SIFT,63 andMutationTaster64 estimate the impact of amino
acid substitutions on the respective protein and are
frequently used for prioritizing variants discovered from
exome-sequencing projects. Our method could potentially
be used in conjunction with these tools for the generation
of hypotheses regarding the molecular mechanisms of the
deleterious variants discovered. Moreover, it might be
interesting to consider the penetrance and expressivity of
the disease mutations in future analyses,65,66 when suffi-
cient information is available.
In conclusion, by integrating inheritance information
with atomic-resolution structural details of protein interac-
tions, our analysis provides an approach to predicting
functional consequences at the molecular level for both
in-frame and truncating mutations, especially those
discovered by various ongoing genome-sequencing efforts.Supplemental Data
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